Society of Nuclear Medicine and Molecular Imaging
@snm-mi.bsky.social
An international scientific and medical organization dedicated to raising public awareness about molecular imaging. Learn more at https://linktr.ee/snmmi
FEATURED: First-in-Human Study of [211At]NaAt as Targeted α-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial)
Read here: jnm.snmjournals.org/content/66/1...
Read here: jnm.snmjournals.org/content/66/1...
December 3, 2025 at 9:35 PM
FEATURED: First-in-Human Study of [211At]NaAt as Targeted α-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial)
Read here: jnm.snmjournals.org/content/66/1...
Read here: jnm.snmjournals.org/content/66/1...
FEATURED: PET Imaging of System A Amino Acid Transport Detects Early Response to Immune Checkpoint Inhibitor Therapy in a Syngeneic Mouse Model
Read here: jnm.snmjournals.org/content/66/1...
Read here: jnm.snmjournals.org/content/66/1...
December 3, 2025 at 9:35 PM
FEATURED: PET Imaging of System A Amino Acid Transport Detects Early Response to Immune Checkpoint Inhibitor Therapy in a Syngeneic Mouse Model
Read here: jnm.snmjournals.org/content/66/1...
Read here: jnm.snmjournals.org/content/66/1...
Is It Really Happening? α-Therapy and Combination Strategies to Overcome Resistance and Enhance Clinical Outcomes in Prostate Cancer
Read here: jnm.snmjournals.org/content/66/1...
Read here: jnm.snmjournals.org/content/66/1...
December 3, 2025 at 9:34 PM
Is It Really Happening? α-Therapy and Combination Strategies to Overcome Resistance and Enhance Clinical Outcomes in Prostate Cancer
Read here: jnm.snmjournals.org/content/66/1...
Read here: jnm.snmjournals.org/content/66/1...
The State of the Art: Current Developments in Combining External-Beam Radiotherapy and 177Lu-Labeled PSMA Ligands for Prostate Cancer Treatment
Read here: jnm.snmjournals.org/content/66/1...
Read here: jnm.snmjournals.org/content/66/1...
December 3, 2025 at 9:34 PM
The State of the Art: Current Developments in Combining External-Beam Radiotherapy and 177Lu-Labeled PSMA Ligands for Prostate Cancer Treatment
Read here: jnm.snmjournals.org/content/66/1...
Read here: jnm.snmjournals.org/content/66/1...
Discussions with Leaders: Translating Discovery into Impact with Caius Radu
Read here: jnm.snmjournals.org/content/66/1...
Read here: jnm.snmjournals.org/content/66/1...
December 3, 2025 at 9:34 PM
Discussions with Leaders: Translating Discovery into Impact with Caius Radu
Read here: jnm.snmjournals.org/content/66/1...
Read here: jnm.snmjournals.org/content/66/1...
A 100% Complete Response Rate Shows Promise--85% of mice also achieved histologic cure. 1 and 2-cycle treatments were equally effective and well-tolerated. In the patient xenograft, a single 225Ac treatment achieved a 60% response and prolonged survival compared to no treatment.
November 10, 2025 at 3:27 PM
A 100% Complete Response Rate Shows Promise--85% of mice also achieved histologic cure. 1 and 2-cycle treatments were equally effective and well-tolerated. In the patient xenograft, a single 225Ac treatment achieved a 60% response and prolonged survival compared to no treatment.
Though previous studies have shown that HER2-targeted radiotherapies with the alpha-particle-emitting radionuclide 225Ac were effective, they were not safe for patients, as 225Ac was retained in the body, causing high toxicity.
November 10, 2025 at 3:27 PM
Though previous studies have shown that HER2-targeted radiotherapies with the alpha-particle-emitting radionuclide 225Ac were effective, they were not safe for patients, as 225Ac was retained in the body, causing high toxicity.
FEATURED: CXCR4 PET/CT Predicts Left Ventricular Recovery 8 Months After Acute Myocardial Infarction: jnm.snmjournals.org/content/66/1...
November 4, 2025 at 3:28 PM
FEATURED: CXCR4 PET/CT Predicts Left Ventricular Recovery 8 Months After Acute Myocardial Infarction: jnm.snmjournals.org/content/66/1...
FEATURED: 225Ac α-Pretargeted Radioimmunotherapy of Human Epidermal Growth Factor Receptor 2–Expressing Breast Cancer: jnm.snmjournals.org/content/66/1...
November 4, 2025 at 3:28 PM
FEATURED: 225Ac α-Pretargeted Radioimmunotherapy of Human Epidermal Growth Factor Receptor 2–Expressing Breast Cancer: jnm.snmjournals.org/content/66/1...
The State of the Art: Comparison, Agreement, and Significance Cutoffs of 18F-Flurpiridaz PET Myocardial Blood Flow Quantitation Methods and Software Packages: jnm.snmjournals.org/content/66/1...
November 4, 2025 at 3:28 PM
The State of the Art: Comparison, Agreement, and Significance Cutoffs of 18F-Flurpiridaz PET Myocardial Blood Flow Quantitation Methods and Software Packages: jnm.snmjournals.org/content/66/1...
Discussions with Leaders: Translating Research Amidst Transnational Quarrels: jnm.snmjournals.org/content/66/1...
November 4, 2025 at 3:27 PM
Discussions with Leaders: Translating Research Amidst Transnational Quarrels: jnm.snmjournals.org/content/66/1...
Such great timing!
October 7, 2025 at 2:16 PM
Such great timing!